Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma.

Schillaci O, DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, O'Donnell RT, Lamborn KR.

Cancer Biother Radiopharm. 2007 Aug;22(4):521-30.

PMID:
17803447
2.

Nuclear/radiological terrorism: emergency department management of radiation casualties.

Bushberg JT, Kroger LA, Hartman MB, Leidholdt EM Jr, Miller KL, Derlet R, Wraa C.

J Emerg Med. 2007 Jan;32(1):71-85. Review.

PMID:
17239736
3.

Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry.

Shen S, DeNardo SJ, Richman CM, Yuan A, Siantar CH, O'Donnell RT, Kroger LA, DeNardo GL.

J Nucl Med. 2005 Jun;46(6):1034-41.

4.

Characterization of human IgG antimouse antibody in patients with B-cell malignancies.

DeNardo GL, Mirick GR, Kroger LA, Bradt BM, Lamborn KR, DeNardo SJ.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):4013S-21S.

5.

Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy.

Winthrop MD, DeNardo SJ, Albrecht H, Mirick GR, Kroger LA, Lamborn KR, Venclovas C, Colvin ME, Burke PA, DeNardo GL.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3845S-53S.

6.

Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.

Tuscano JM, O'Donnell RT, Miers LA, Kroger LA, Kukis DL, Lamborn KR, Tedder TF, DeNardo GL.

Blood. 2003 May 1;101(9):3641-7. Epub 2003 Jan 2.

7.
8.

Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy.

Kroger LA, DeNardo GL, Gumerlock PH, Xiong CY, Winthrop MD, Shi XB, Mack PC, Leshchinsky T, DeNardo SJ.

Cancer Biother Radiopharm. 2001 Jun;16(3):213-25.

PMID:
11471486
9.

Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.

O'Donnell RT, DeNardo SJ, Miers LA, Kukis DL, Mirick GR, Kroger LA, DeNardo GL.

Cancer Biother Radiopharm. 1998 Oct;13(5):351-61.

PMID:
10851425
10.

Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.

DeNardo GL, DeNardo SJ, Lamborn KR, Goldstein DS, Levy NB, Lewis JP, O'Grady LF, Raventos A, Kroger LA, Macey DJ, McGahan JP, Mills SL, Shen S.

Cancer Biother Radiopharm. 1998 Aug;13(4):239-54.

PMID:
10850360
11.

Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody.

DeNardo SJ, Kroger LA, MacKenzie MR, Mirick GR, Shen S, DeNardo GL.

Cancer Biother Radiopharm. 1998 Feb;13(1):1-12.

PMID:
10850337
12.

Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.

O'Donnell RT, Leigh BR, Christensen SD, Goldstein DS, Kukis DL, Shen S, Yuan A, DeNardo DA, Kroger LA, DeNardo GL.

Cancer Biother Radiopharm. 1999 Jun;14(3):167-76.

PMID:
10850301
13.

Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.

DeNardo GL, O'Donnell RT, Shen S, Kroger LA, Yuan A, Meares CF, Kukis DL, DeNardo SJ.

J Nucl Med. 2000 May;41(5):952-8.

14.

Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy.

DeNardo SJ, Burke PA, Leigh BR, O'Donnell RT, Miers LA, Kroger LA, Goodman SL, Matzku S, Jonczyk A, Lamborn KR, DeNardo GL.

Cancer Biother Radiopharm. 2000 Feb;15(1):71-9.

PMID:
10740655
15.

Effect of 67Cu-2IT-BAT-Lym-1 therapy on BCL-2 gene and protein expression in a lymphoma mouse model.

Kroger LA, DeNardo SJ, DeNardo GL, Xiong CY, Winthrop MD, Gumerlock PH.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3010s-3014s.

PMID:
10541336
16.

Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.

Richman CM, DeNardo SJ, O'Donnell RT, Goldstein DS, Shen S, Kukis DL, Kroger LA, Yuan A, Boniface GR, Griffith IJ, DeNardo GL.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3243s-3248s.

PMID:
10541370
17.

Strategies for developing effective radioimmunotherapy for solid tumors.

DeNardo GL, O'Donnell RT, Kroger LA, Richman CM, Goldstein DS, Shen S, DeNardo SJ.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3219s-3223s. Review.

PMID:
10541367
18.

Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics.

DeNardo SJ, DeNardo GL, DeNardo DG, Xiong CY, Shi XB, Winthrop MD, Kroger LA, Carter P.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3213s-3218s.

PMID:
10541366
19.

A new era for radiolabeled antibodies in cancer?

DeNardo SJ, Kroger LA, DeNardo GL.

Curr Opin Immunol. 1999 Oct;11(5):563-9. Review.

PMID:
10508716
20.

Milestones in the development of Lym-1 therapy.

DeNardo GL, O'Donnell RT, Rose LM, Mirick GR, Kroger LA, DeNardo SJ.

Hybridoma. 1999 Feb;18(1):1-11. Review.

PMID:
10211782
21.

67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.

DeNardo SJ, DeNardo GL, Kukis DL, Shen S, Kroger LA, DeNardo DA, Goldstein DS, Mirick GR, Salako Q, Mausner LF, Srivastava SC, Meares CF.

J Nucl Med. 1999 Feb;40(2):302-10.

22.

Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol.

Denardo SJ, Richman CM, Kukis DL, Shen S, Lamborn KR, Miers LA, Kroger LA, Perez EA, Denardo GL.

Anticancer Res. 1998 Nov-Dec;18(6A):4011-8.

PMID:
9891439
23.

Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.

DeNardo GL, Kroger LA, Meares CF, Richman CM, Salako Q, Shen S, Lamborn KR, Peterson JJ, Miers LA, Zhong GR, DeNardo SJ.

Clin Cancer Res. 1998 Oct;4(10):2483-90.

24.

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.

DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, Lamborn KR, Levy NB, McGahan JP, Salako Q, Shen S, Lewis JP.

J Clin Oncol. 1998 Oct;16(10):3246-56.

PMID:
9779698
25.

L6 monoclonal antibody binds prostate cancer.

O'Donnell RT, DeNardo SJ, Shi XB, Mirick GR, DeNardo GL, Kroger LA, Meyers FJ.

Prostate. 1998 Oct 1;37(2):91-7.

PMID:
9759703
26.

Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.

Denardo GL, Denardo SJ, Kukis DL, O'Donnell RT, Shen S, Goldstein DS, Kroger LA, Salako Q, Denardo DA, Mirick GR, Mausner LF, Srivastava SC, Meares CF.

Anticancer Res. 1998 Jul-Aug;18(4B):2779-88.

PMID:
9713461
27.

New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor.

Feng X, Pak RH, Kroger LA, Moran JK, DeNardo DG, Meares CF, DeNardo GL, DeNardo SJ.

Hybridoma. 1998 Apr;17(2):125-32.

PMID:
9627052
28.

Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.

DeNardo SJ, Kukis DL, Miers LA, Winthrop MD, Kroger LA, Salako Q, Shen S, Lamborn KR, Gumerlock PH, Meares CF, DeNardo GL.

J Nucl Med. 1998 May;39(5):842-9.

29.

Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

DeNardo GL, Lamborn KR, Goldstein DS, Kroger LA, DeNardo SJ.

Cancer. 1997 Dec 15;80(12 Suppl):2706-11.

PMID:
9406728
30.

Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma.

DeNardo SJ, Kroger LA, Lamborn KR, Miers LA, O'Donnell RT, Kukis DL, Richman CM, DeNardo GL.

Cancer. 1997 Dec 15;80(12 Suppl):2583-90.

PMID:
9406713
31.

Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies.

Lamborn KR, DeNardo GL, DeNardo SJ, Goldstein DS, Shen S, Larkin EC, Kroger LA.

Clin Cancer Res. 1997 Aug;3(8):1253-60.

32.

Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody.

Denardo SJ, O'Grady LF, Richman CM, Goldstein DS, O'Donnell RT, Denardo DA, Kroger LA, Lamborn KR, Hellström KE, Hellström I, Denardo GL.

Anticancer Res. 1997 May-Jun;17(3B):1745-51.

PMID:
9179228
33.

Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.

DeNardo SJ, Kukis DL, Kroger LA, O'Donnell RT, Lamborn KR, Miers LA, DeNardo DG, Meares CF, DeNardo GL.

Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4000-4.

34.

Antibody responses to macrocycles in lymphoma.

DeNardo GL, Mirick GR, Kroger LA, O'Donnell RT, Meares CF, DeNardo SJ.

J Nucl Med. 1996 Mar;37(3):451-6.

35.

Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies.

DeNardo GL, Lamborn KR, DeNardo SJ, Goldstein DS, Dolber-Smith EG, Kroger LA, Larkin EC, Shen S.

Cancer Res. 1995 Dec 1;55(23 Suppl):5893s-5898s.

36.

Analysis of antiglobulin (HAMA) response in a group of patients with B-lymphocytic malignancies treated with 131I-Lym-1.

De Nardo GL, Kroger LA, Mirick GR, Lamborn KR, De Nardo SJ.

Int J Biol Markers. 1995 Apr-Jun;10(2):67-74.

PMID:
7561241
37.

Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131I-Lym-1 as a model.

DeNardo GL, DeNardo SJ, Macey DJ, Shen S, Kroger LA.

Cancer. 1994 Feb 1;73(3 Suppl):1038-48.

PMID:
8306246
38.

The biologic window for chimeric L6 radioimmunotherapy.

DeNardo SJ, Mirick GR, Kroger LA, O'Grady LF, Erickson KL, Yuan A, Lamborn KR, Hellstrom I, Hellstrom KE, DeNardo GL.

Cancer. 1994 Feb 1;73(3 Suppl):1023-32.

PMID:
8306244
39.

Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3).

DeNardo GL, Kroger LA, DeNardo SJ, Miers LA, Salako Q, Kukis DL, Fand I, Shen S, Renn O, Meares CF.

Cancer. 1994 Feb 1;73(3 Suppl):1012-22.

PMID:
8306243
40.

Use of response surface statistical designs to detect effects of biologic response modifiers such as IL-2.

DeNardo GL, Lamborn KR, DeNardo SJ, Kroger LA.

Biotechnol Ther. 1994;5(1-2):15-26.

PMID:
7703830
41.

Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: phase I study.

Kramer EL, DeNardo SJ, Liebes L, Kroger LA, Noz ME, Mizrachi H, Salako QA, Furmanski P, Glenn SD, DeNardo GL, et al.

J Nucl Med. 1993 Jul;34(7):1067-74.

42.
43.

Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy.

DeNardo SJ, O'Grady LF, Macey DJ, Kroger LA, DeNardo GL, Lamborn KR, Levy NB, Mills SL, Hellstrom I, Hellstrom KE.

Int J Rad Appl Instrum B. 1991;18(6):621-31.

PMID:
1743985

Supplemental Content

Loading ...
Support Center